Hodgkin's Lymphoma Market Insight, Epidemiology and Market Forecast - 2036

Key Highlights

• The total market size in the 7MM for Hodgkin lymphoma is expected to grow with a significant CAGR during the forecast period (2026-2036).
• In 2023, the US accounted for the maximum share of the total market in the 7MM.
• In 2024, an estimated 8,570 (4,630 in males and 3,940 in females) new cases of Hodgkin lymphoma are expected in the United States.
• Hodgkin lymphoma generally has a positive outlook, with majority of patients achieving long-term remission under current treatment protocols.
• The integration of chemotherapy, radiation therapy, and emerging treatments enables personalized treatment strategies tailored to the unique needs of each patient, optimizing therapeutic efficacy and improving overall care.
• In the UK Hodgkin lymphoma incidence rates increase significantly during childhood, peaking between ages 20 and 29. After this peak, the rates fluctuate, with notable rises at ages 35-39 and again between 75 and 84.
• The highest incidence rates are seen in females aged 20-24 and males aged 75-79. Over 80% of Hodgkin lymphoma patients can be cured with current treatment approaches. The cure rate is even higher, nearing 90%, for younger patients and those with early-stage favorable disease.
• In October 2023, European Commission Approves ADCETRIS (brentuximab vedotin) for the treatment of adult patients with previously untreated CD30+ Stage III Hodgkin Lymphoma in combination with doxorubicin, vinblastine and dacarbazine (AVD).
• The Hodgkin lymphoma has a strong pipeline, with many companies actively developing therapies. Key players include Merck, Bristol Myers Squibb, Takeda, Pfizer, Genmab and others.

The “Hodgkin Lymphoma - Market Insights, Epidemiology, and Market Forecast - 2036” report delivers an in-depth understanding of Hodgkin lymphoma, historical and forecasted epidemiology as well as Hodgkin lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Hodgkin lymphoma market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Hodgkin Lymphoma market size from 2022 to 2036. The report also covers current Hodgkin lymphoma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.a

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Hodgkin Lymphoma: Understanding and Treatment Algorithm

Hodgkin Lymphoma Overview

Hodgkin lymphoma is a type of cancer that originates in the lymphatic system and is identified by the presence of Reed-Sternberg cells. It represents one of the two major categories of lymphoma, the other being non-Hodgkin lymphoma. When found and treated early, it has a notably high cure rate. In this disease, B-cells grow abnormally and build up in areas such as the lymph nodes, impairing their normal infection-fighting function and making the body more susceptible to illness. The condition is divided into two primary forms: classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Although it can be fast-growing and spread rapidly, Hodgkin lymphoma remains among the most treatable types of cancer.

Hodgkin Lymphoma Diagnosis

The initial assessment for Hodgkin lymphoma uses several diagnostic methods, beginning with a biopsy of the affected lymph nodes or tissues. The sample is then examined using immunophenotyping to determine which proteins the cells produce. Imaging tests - including CT scans, X-rays, and PET scans of the chest, abdomen, and pelvis - are performed to look for enlarged lymph nodes or spleen, as well as any unusual changes such as abnormal retinal veins. PET scans are particularly helpful for identifying patients who may be treated with chemotherapy alone, reducing the need for radiotherapy and its associated long-term risks, including heart problems or secondary cancers. Blood tests are also carried out to evaluate general health, measure red and white blood cell levels, check platelet counts, and assess the function of organs such as the liver and kidneys. Additionally, Fluorescence in Situ Hybridization (FISH) is used to examine cellular genes or chromosomes, allowing detection of specific chromosomal abnormalities.

Once diagnostic testing is complete, the next step is to determine how far the disease has progressed. Staging describes the extent of the cancer within or beyond the lymphatic system. Hodgkin lymphoma is classified from stage I - where only a single lymph node region or lymphatic structure is affected - to stage IV, in which the disease has spread outside the lymphatic system to other organs.

Hodgkin Lymphoma Treatment

Treatment for Hodgkin lymphoma typically includes a tailored mix of chemotherapy, radiation therapy, and targeted agents based on the disease’s stage and type. For advanced cases, chemotherapy protocols such as ABVD (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine) remain standard. Targeted options like ADCETRIS and immune-based therapies including OPDIVO and KEYTRUDA play an important role, especially in patients whose disease has relapsed or does not respond to initial treatment. However, despite therapeutic progress, the development pipeline for Hodgkin lymphoma is progressing slowly. The limited number of new drug candidates under investigation may restrict future advancements and improvements in patient care.Further details related to treatment are provided in the report…

Hodgkin Lymphoma Epidemiology

The Hodgkin lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total Incident Cases of Hodgkin lymphoma, stage-specific incident cases of Hodgkin lymphoma, type-specific incident cases of Hodgkin lymphoma, age-specific incident cases of Hodgkin lymphoma, gender-specific incident cases of Hodgkin lymphoma, and treatable cases of Hodgkin lymphoma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2022 to 2036.

• The total number of incident cases of Hodgkin lymphoma in the 7MM was maximum in the US during the forecasted period.
• Hodgkin lymphoma is rare in children younger than 5 years old. But it's the most common cancer diagnosed in adolescent’s ages 15 to 19 years.
• In the UK, 42% of Hodgkin lymphoma cases occur in females, while 58% occur in males.
• The distribution of classical Hodgkin lymphoma subtypes is as follows: nodular sclerosis classical Hodgkin lymphoma (70%), mixed cellularity classical HL (25%), lymphocyte-rich classical Hodgkin lymphoma (5%), and lymphocyte-depleted classical HL (less than 1%). Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for about 5% of all Hodgkin lymphoma cases.

Hodgkin Lymphoma Drug Chapters

The drug chapter segment of the Hodgkin lymphoma report encloses a detailed analysis of the marketed and the late, mid, and early stage (Phase III, Phase II, and Phase I/II) pipeline drugs. The marketed drugs segment encloses drugs such as KEYTRUDA (Merck Sharp & Dohme), OPDIVO (Bristol Myers Squibb), and ADCENTRIS (Pfizer & Takeda). The drug chapter also helps understand the Hodgkin lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

Marketed Drugs

KEYTRUDA (pembrolizumab): Merck

This anti-PD-1 treatment enhances the body’s immune system by improving its ability to recognize and attack tumor cells. KEYTRUDA is a humanized monoclonal antibody that inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which in turn stimulates T lymphocytes that can act on both cancerous and normal cells.

In October 2020, the U.S. Food and Drug Administration (FDA) granted an expanded indication for KEYTRUDA, the anti-PD-1 therapy developed by Merck, allowing its use as a standalone treatment for adults with relapsed or refractory classical Hodgkin lymphoma.

The decision was made under the FDA’s accelerated approval pathway, supported by tumor response outcomes and the durability of those responses. The approval drew on findings from 210 participants in the KEYNOTE-087 study, where KEYTRUDA (200 mg every three weeks) demonstrated an overall response rate of 69% (95% CI: 62-75), including a complete remission rate of 22% and a partial remission rate of 47%.

OPDIVO (nivolumab): Bristol Myers Squibb

When the ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T cells, they suppress T-cell proliferation and the release of cytokines. Many tumors increase the expression of these PD-1 ligands, and activation of this pathway can reduce the immune system’s ability to detect and attack cancer cells. Nivolumab is a human IgG4 monoclonal antibody that attaches to the PD-1 receptor, preventing its interaction with PD-L1 and PD-L2. By blocking this pathway, nivolumab lifts PD-1-mediated immune suppression, enhancing overall immune activity, including anti-tumor responses. In mouse models with syngeneic tumors, inhibition of PD-1 signaling led to reduced tumor growth.

In May 2016, the U.S. Food and Drug Administration granted accelerated approval to OPDIVO (nivolumab) for treating patients with classical Hodgkin lymphoma (cHL). This approval came before the scheduled PDUFA decision date of September 1, 2016. The therapy was also awarded Breakthrough Therapy Designation for patients with relapsed or refractory cHL who had not responded to autologous HSCT and brentuximab vedotin. Additionally, OPDIVO received Orphan Drug status for Hodgkin lymphoma and was reviewed under Priority Review as part of the FDA’s Accelerated Approval Program.

ADCETRIS (brentuximab vedotin): Pfizer & Takeda

It is an antibody-drug conjugate (ADC) consisting of an anti-CD30 monoclonal antibody linked through a protease-cleavable connector to the microtubule-disrupting compound monomethyl auristatin E (MMAE), created using Seagen’s specialized technology. The linker is engineered to remain stable while circulating in the blood, but to release MMAE once the ADC is taken up by CD30-expressing cancer cells. The therapy has been authorized for marketing in more than 70 countries for use in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL).

In November 2022, the FDA granted approval for its use, together with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide, in children aged two and older who have newly diagnosed, high-risk classical Hodgkin lymphoma. This represents the first pediatric indication for brentuximab vedotin.

Emerging Drugs

TEVIMBRA (tislelizumab): BeiGene

TEVIMBRA is a monoclonal antibody belonging to a class of therapies that inhibit the PD-1/PD-L1 pathway. By blocking this interaction, it lifts restraints on the immune system, which can interfere with peripheral tolerance and may result in immune-related adverse effects.

In August 2024, BeiGene announced the completion of a Phase II study evaluating tislelizumab in individuals with relapsed or refractory classical Hodgkin lymphoma (TIRHOL).

The company also reported in March 2024 that a separate Phase II trial assessing tislelizumab as a first-line therapy for Hodgkin lymphoma in patients aged 60 and older is underway, with projected completion in 2028.

Favezelimab/pembrolizumab: Merck

Favezelimab attaches to LAG3 on tumor-infiltrating lymphocytes (TILs), preventing its interaction with MHC class II molecules found on tumor cells. Merck is advancing a combined formulation of favezelimab and pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma and is currently running a Phase III study.

In Phase I/II data reported at ASCO 2024, the overall response rate (ORR) was 83% (n = 25; 95% CI, 65-94). Eleven patients (37%) achieved a complete response, while fourteen (47%) had a partial response. The median duration of response was 17.0 months (range, 2.6-30.5), with an estimated 47% of responders still in response at 24 months. Median progression-free survival was 19.4 months (95% CI, 9.5-28.5), and the 24-month PFS rate was 46%. Continued follow-up showed that the favezelimab-pembrolizumab combination maintained durable antitumor activity with an acceptable safety profile in patients with anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma.

Drug Class Insights

The drug classes include cell death stimulants, CD30 and CD3 binders, and PD-L1 and PD-L2 antagonists. Additionally, there are tumor cell inhibitors and immune-modulating agents.

PD-1 inhibitors

PD-L1 and PD-L2 both inhibit T-cell growth, cytokine release, and adhesion, though some evidence indicates they might also provide costimulatory signals. Unlike PD-L1, PD-L2 can initiate reverse signaling in dendritic cells, promoting IL-12 secretion and subsequent T-cell activation. Their expression is driven by different regulatory cues, suggesting they share some immune functions while also carrying out distinct roles. The immunotherapies KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab) both work by blocking the PD-1 receptor, preventing it from binding PD-L1 or PD-L2 and thereby enhancing antitumor T-cell activity. Although their mechanisms largely overlap, OPDIVO may bind PD-1 with slightly greater affinity, which could affect its potency, dosing requirements, side-effect profile, and overall clinical performance.

Hodgkin Lymphoma Market Outlook

Hodgkin lymphoma is a type of cancer that develops in the lymph nodes and often leads to swelling in areas like the neck, armpits, and groin. Market growth for treatments is largely fueled by the rising number of special designations granted by regulatory bodies. Increased investment in healthcare infrastructure, the growing use of high-priced therapies such as immune checkpoint inhibitors, and government initiatives to boost awareness in underserved areas are also supporting this expansion. In addition, the widening opportunities in emerging markets, along with the rising interest in regenerative medicine, are expected to create substantial prospects for industry growth. Partnerships and strategic alliances among companies further contribute to the positive market trajectory.

Compared with non-Hodgkin lymphoma, Hodgkin lymphoma is relatively rare and most often affects adults aged 20-39 and those over 65. More than three-quarters of adult patients achieve remission with standard therapies like chemotherapy and radiation. ADCETRIS (brentuximab vedotin), which targets the CD30 protein found on Hodgkin lymphoma cells, is approved for advanced disease and may allow older patients to avoid more toxic chemotherapy regimens. Ongoing clinical trials are assessing its use in combination with other treatments, and the drug is also approved for pediatric and adolescent patients. Immune checkpoint inhibitors such as nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA) have shown strong results in recurrent cases and are being investigated in combination therapies. Additional targeted approaches, including anti-CD30 antibodies like SGN-35, demonstrate potential for both newly diagnosed and relapsed patients. Research is also underway into personalized treatments such as adoptive immunotherapy directed at EBV-related antigens and biotoxins designed to target tumor-associated macrophages.

In summary, multiple new therapies are anticipated to enter the treatment landscape for Hodgkin lymphoma in the coming years. Demand for these emerging options is likely to grow due to physician interest, significant unmet clinical needs, frequent therapy switching, and the increasing use of multidrug treatment strategies.

• Among the 7MM, the United States expected to capture the maximum market share in 2036 and expected to grow in the coming years.
• In the EU4 and the UK, Germany expected to capture the maximum share by 2036.
• Presently two PD-1 inhibitors namely KEYTRUDA and OPDIVO are approved and a new one TEVIMBRA is currently under Phase II of the clinical trial process for the treatment of relapsed or refractory classical Hodgkin lymphoma.
• Personalized therapies based on PET2 imaging have emerged as a promising strategy, showing impressive three-year progression-free survival (PFS) rates and supporting a more tailored, precise treatment approach.
• In June 2024, Takeda and Pfizer announced that the German Hodgkin Study Group (GHSG) would present positive results from the Phase III HD21 trial of ADCETRIS (brentuximab vedotin) combined with chemotherapy in late-breaking oral presentations at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and the 29th European Hematology Association (EHA) Annual Meeting.

Hodgkin Lymphoma Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2020-2034. The landscape of Hodgkin lymphoma treatment has experienced a profound transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, oncology professionals, and the entire healthcare community in their tireless pursuit of advancing cancer care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Hodgkin lymphoma Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Hodgkin lymphoma emerging therapy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Hodgkin lymphoma evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including oncologists, radiation oncologists, surgical oncologists, and others.

The analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 7+ KOLs in the 7MM. Centers such as - Memorial Sloan Kettering Cancer Center, Mount Sinai, Smilow Cancer Hospital Yale Cancer Center, National Institutes of Health in the USA, Moffitt Cancer Center, MD Anderson Cancer Center Madrid, Moffitt Cancer Center in Florida, University of Miami, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Hodgkin lymphoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event- free survival, one of the most crucial primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and this clearly explains the drugs side effects in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Hodgkin lymphoma, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Hodgkin lymphoma market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Hodgkin lymphoma market.

Hodgkin Lymphoma Report Insights

• Patient Population
• Therapeutic Approaches
• Hodgkin lymphoma Pipeline Analysis
• Hodgkin lymphoma Market Size and Trends
• Existing and Future Market Opportunity

Hodgkin Lymphoma Report Key Strengths

• Eleven-Year Forecast
• The 7MM Coverage
• Hodgkin Lymphoma Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Hodgkin Lymphoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT Analysis and Conjoint Analysis)

FAQs

• What was the Hodgkin lymphoma market size, the market size by therapies, market share (%) distribution in 2023, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for approved therapies?
• What can be the future treatment paradigm of Hodgkin lymphoma?
• What are the disease risks, burdens, and unmet needs of Hodgkin lymphoma? What will be the growth opportunities across the 7MM concerning the patient population with Hodgkin lymphoma?
• What are the current options for the treatment of Hodgkin lymphoma? What are the current guidelines for treating Hodgkin lymphoma in the US, Europe, and Japan?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?

Reasons to Buy

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Hodgkin lymphoma market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Analyst view section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.